| Detected | Trial | Change |
|---|---|---|
| 2026-06-11 | NCT05100862 A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants… |
Sponsor changed: BeiGene -> BeOne Medicines |
| 2026-06-06 | NCT07299019 A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis |
Trial sites expanded: 9 -> 12 locations |
| 2026-06-02 | NCT04739813 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-02 | NCT04739813 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With… |
Enrollment reduced: 55 -> 34 participants |
| 2026-06-02 | NCT04739813 Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With… |
date change Primary completion moved earlier: 2026-06-18 -> 2026-05-07 |
| 2026-05-30 | NCT04077723 A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of… |
Trial sites reduced: 44 -> 35 locations |
| 2026-05-27 | NCT04889716 CAR-T Followed by Bispecific Antibodies |
Primary endpoint(s) modified |
| 2026-05-27 | NCT04889716 CAR-T Followed by Bispecific Antibodies |
Enrollment reduced: 42 -> 23 participants |
| 2026-05-20 | NCT07299019 A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis |
Trial sites expanded: 5 -> 8 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-08 | NCT07634289 Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell… | Phase 2 | Not Yet Recruiting |
| 2026-06-03 | NCT07624799 Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy… | Phase 2 | Not Yet Recruiting |
| 2026-05-29 | NCT07613788 Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL | Phase 2 | Not Yet Recruiting |
| 2026-05-20 | NCT07599423 A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With… | Phase 2 | Not Yet Recruiting |
| 2026-05-15 | NCT07591467 Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive… | Phase 3 | Not Yet Recruiting |
| 2026-05-14 | NCT07585747 A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and… | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07355699 | Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously… | Marginal Zone Lymphoma(MZL) | Recruiting |
| Phase 3 | |||
| NCT06781944 | OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous… | Primary Membranous Nephropathy | Recruiting |
| NCT07377578 | A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With… | Mantle Cell Lymphoma | Recruiting |
| NCT06428019 | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT05045664 | Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody | Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a | Recruiting |
| NCT07067463 | A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis | Multiple Sclerosis (MS) Primary Progressive | Recruiting |
| NCT06191744 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral… | Follicular Lymphoma (FL) | Recruiting |
| NCT06084936 | A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in… | Lymphoma | Recruiting |
| NCT06943872 | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT06284122 | Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy… | Follicular Lymphoma | Recruiting |
| NCT07299019 | A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Recruiting |
| NCT05100862 | A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants… | Relapsed/Refractory Follicular Lymphoma | Recruiting |
| NCT04269902 | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT04408638 | A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs… | Diffuse Large B-cell Lymphoma | Active, Not Recruiting |
| NCT04629248 | A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary… | Primary Membranous Nephropathy | Active, Not Recruiting |
| NCT04608318 | Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus… | Chronic Lymphoid Leukemia | Active, Not Recruiting |
| NCT04221477 | A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS… | Lupus Nephritis | Active, Not Recruiting |
| NCT04963296 | A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic… | Systemic Lupus Erythematosus | Active, Not Recruiting |
| NCT07591467 | Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive… | BRCA-Mutated | Not Yet Recruiting |
| NCT05057494 | A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in… | Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Active, Not Recruiting |
| NCT03701282 | Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited… | Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| NCT03737981 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment… | Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| NCT06073821 | Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax… | CLL | Active, Not Recruiting |
| NCT03462719 | A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus… | Leukemia, Lymphocytic, Chronic, B-Cell | Active, Not Recruiting |
| Phase 2 | |||
| NCT04505254 | Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | Recruiting |